4565 — Nxera Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSucker Stock

Annual income statement for Nxera Pharma Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,842	17,712	15,569	12,766	28,835
Cost of Revenue
Gross Profit	8,081	16,779	14,643	9,664	21,219
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	6,451	13,833	13,855	22,176	34,220
Operating Profit	2,391	3,879	1,714	-9,410	-5,385
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,622	433	1,078	-10,680	-4,662
Provision for Income Taxes
Net Income After Taxes	1,479	1,017	382	-7,193	-4,838
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,479	1,017	382	-7,193	-4,838
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,479	1,017	382	-7,193	-4,838
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.975	36.8	13.3	-95.4	-63.3
Dividends per Share